Sukhija Remy 4

Accession 0000899243-22-039463

CIK 0001157601other

View on SEC.gov Company Profile

Filed

Dec 27, 7:00 PM ET

Accepted

Dec 28, 8:00 PM ET

Size

40.4 KB

Accession

0000899243-22-039463

Insider Transaction Report

Form 4

Period: 2022-12-23

MADRIGAL PHARMACEUTICALS, INC.MDGL

Sukhija Remy

SVP and Chief Comm'l Officer

Transactions

Sale
Common Stock
2022-12-23$282.13/sh−400$112,852→ 500 total
Sale
Common Stock
2022-12-23$279.15/sh−3,003$838,287→ 4,520 total
Exercise/Conversion
Stock Option (Right to Buy)
2022-12-23−30,000→ 30,000 total
Exercise: $60.26Exp: 2030-04-01→ Common Stock (30,000 underlying)
Exercise/Conversion
Common Stock
2022-12-23$60.26/sh+30,000$1,807,800→ 30,000 total
Sale
Common Stock
2022-12-23$267.47/sh−1,107$296,089→ 28,300 total
Sale
Common Stock
2022-12-23$269.61/sh−1,476$397,944→ 24,911 total
Sale
Common Stock
2022-12-23$272.68/sh−5,534$1,509,011→ 15,224 total
Sale
Common Stock
2022-12-23$277.83/sh−700$194,481→ 7,523 total
Sale
Common Stock
2022-12-23$280.92/sh−1,000$280,920→ 900 total
Sale
Common Stock
2022-12-23$283.43/sh−400$113,372→ 100 total
Sale
Common Stock
2022-12-23$266.04/sh−593$157,762→ 29,407 total
Sale
Common Stock
2022-12-23$268.50/sh−1,913$513,641→ 26,387 total
Sale
Common Stock
2022-12-23$271.54/sh−2,084$565,889→ 20,758 total
Sale
Common Stock
2022-12-23$273.54/sh−2,471$675,917→ 12,753 total
Sale
Common Stock
2022-12-23$270.56/sh−2,069$559,789→ 22,842 total
Sale
Common Stock
2022-12-23$274.56/sh−3,019$828,897→ 9,734 total
Sale
Common Stock
2022-12-23$276.67/sh−700$193,669→ 8,223 total
Sale
Common Stock
2022-12-23$279.96/sh−2,620$733,495→ 1,900 total
Sale
Common Stock
2022-12-23$284.65/sh−100$28,465→ 0 total
Sale
Common Stock
2022-12-23$275.70/sh−811$223,593→ 8,923 total

Footnotes (19)

[F1]All transactions reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After giving effect to these transactions, the reporting person's Rule 10b5-1 trading plan has been concluded and no more trading will be conducted thereunder.
[F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $273.04 to $274.01, inclusive.
[F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.19 to $275.13, inclusive.
[F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $275.24 to $276.23, inclusive.
[F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.40 to $277.31, inclusive.
[F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.49 to $278.13, inclusive.
[F15]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $278.53 to $279.50, inclusive.
[F16]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $279.56 to $280.42, inclusive.
[F17]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $280.61 to $281.44, inclusive.
[F18]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $282.00 to $282.20, inclusive.
[F19]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $283.11 to $283.83, inclusive.
[F2]All shares issued pursuant to the exercise of the options reported herein represent 30,000 shares underlying an overall option award of 60,000 shares. All exercised options had vested. As to the overall option for 60,000 shares, 25% of the shares underlying the option vested on April 1, 2021 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $265.76 to $266.75, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $266.98 to $267.85, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $268.00 to $268.82, inclusive.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $269.01 to $269.95, inclusive.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $270.04 to $271.01, inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $271.04 to $272.01, inclusive.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $272.04 to $273.02, inclusive.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

MADRIGAL PHARMACEUTICALS, INC.

CIK 0001157601

→

Entity typeother

Related Parties

filerCIK 0001806949

Filing Metadata

Form type: 4
Filed: Dec 27, 7:00 PM ET
Accepted: Dec 28, 8:00 PM ET
Size: 40.4 KB

View on SEC.gov